Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652092 · ClinicalTrials.gov registry record · NA
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
A NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01652092: Active NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01652092 is a NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 57 participants, above the 27-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (111% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01652092, a NA study of Chronic Granulomatous Disease and Common Variable Immunodeficiency, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Primary Outcome
Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Alemtuzumab 0.3 mg
- BIOLOGICAL Stem Cell Transplantation
- DRUG Fludarabine phosphate 40 mg
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-09-04 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT01652092 still lists
NCT01652092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, above the 27-participant average among 10 other Chronic Granulomatous Disease trials with a reported enrollment target (111% higher).
The record links to 10 conditions, with Chronic Granulomatous Disease appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01652092 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01652092 about?
NCT01652092 is a clinical study titled "Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies". This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
What is the current status of trial NCT01652092?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 57 participants. The study started on 2012-09-04. Estimated completion is 2026-12.
What conditions does trial NCT01652092 study?
This clinical trial studies the following conditions: Chronic Granulomatous Disease, Common Variable Immunodeficiency, Wiskott-Aldrich Syndrome, SCI/D, CD40 Ligand Deficiency.
What interventions are being tested in trial NCT01652092?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Alemtuzumab 0.3 mg (DRUG), Stem Cell Transplantation (BIOLOGICAL), Fludarabine phosphate 40 mg (DRUG).
Who is sponsoring clinical trial NCT01652092?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652092 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Granulomatous Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01652092's enrollment target sits among peer trials
57 3rd of 10 higher than 8 of 10 other Chronic Granulomatous Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Granulomatous Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
RECRUITING · Phase 1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
RECRUITING · Phase 1
-
Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)
ACTIVE NOT RECRUITING · Early Phase 1
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
ACTIVE NOT RECRUITING · Phase 1
-
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI